Ceregene

Ceregene was a biotechnology company developing AAV gene therapies for neurological and neurodegenerative diseases, including the investigational CERE-110 nerve growth factor treatment for Alzheimer’s disease. Incorporated in 2000 and historically based in San Diego, it was acquired by Sangamo BioSciences in October 2013. Current standalone operations and headcount are not publicly established.